Welcome to the e-CCO Library!

P719: Identification of differentially expressed genes between AIEC and non-AIEC clinical isolates during in vitro cell infection
Year: 2022
Source: ECCO'22
Authors: Bonet Rossinyol, Q.(1);Camprubí-Font, C.(1);Lopez-Siles, M.(1);Martinez-Medina, M.(1);
Created: Friday, 11 February 2022, 3:56 PM
P719: Symptomatic improvement and long-term stability of ulcerative colitis symptoms over 3 years of ozanimod treatment
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Danese, S.(1)*;Abreu, M.T.(2);Afzali, A.(3);Canavan, J.B.(4);Jain, A.(4);Wu, H.(4);Petersen, A.(4);Panaccione, R.(5);Wolf, D.C.(6);
Created: Friday, 14 July 2023, 11:12 AM
P719: Update of a network meta-analysis of efficacy and safety of different intravenous iron compounds in patients with IBD and anaemia
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Aksan*1,2, H. Işık2, H. H. Radeke1,3, A. Dignass4, J. Stein1,5

Created: Friday, 22 February 2019, 9:41 AM
P720 Recurrent rectovaginal fistula in patients with Crohn’s disease: How can we improve the success rate of graciloplasty? A bi-centric European study in 30 patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Frontali1, M. Rottoli2, A. Chierici1, G. Poggioli2, Y. Panis3

Created: Thursday, 30 January 2020, 10:12 AM
P720: Drug survival of first-line biologics in inflammatory bowel disease: large single-centre experience from UR-CARE
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Hanzel, J.(1)*;Supovec, E.(2);Smrekar, N.(1);Koželj, M.(1);Kurent, T.(1);Štabuc, B.(1);Novak, G.(1);Drobne, D.(1);
Created: Friday, 14 July 2023, 11:12 AM
P720: Efficacy of exclusive enteral nutrition for induction and partial enteral nutrition for maintenance of remission in newly diagnosed paediatric and adolescent Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Ikeda*1, T. Ogashiwa1, Y. Nakamori1, T. Mitsui1, K. Chida1, Y. Hashimoto1, Y. Tamura1, S. Maeda2, H. Kimura1, R. Kunisaki1

Created: Friday, 22 February 2019, 9:41 AM
P720: Is there a difference in trough levels and immunogenicity between Crohn’s disease and ulcerative colitis patients treated with infliximab?
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Perdigoto, C. Macedo*, F. Portela, S. Lopes, M. Ferreira, M. Ferreira, S. Mendes, L. Tomé

Created: Thursday, 21 February 2019, 9:14 AM
P720: Similar risk of infection with SARS-CoV-2 in immunocompromised and immunocompetent patients with inflammatory bowel disease and healthy controls
Year: 2022
Source: ECCO'22
Authors: Kante, B.(1);Vuyyuru, S.K.(1);Gupta, R.(2);Dwivedi, T.(2);Kumar, P.(1);Mundhra, S.(1);Golla, R.(1);Virmani, S.(1);Verma, M.(1);Makharia, G.(1);Ahuja, V.(1);Kedia, S.(1);
Created: Friday, 11 February 2022, 3:56 PM
P720: Use of proton pump inhibitors associated with a markedly increased risk of microscopic colitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bonderup O.*1, Lauge Nielsen G.2, Dall M.3, Pottegård A.3, Hallas J.3

Created: Wednesday, 20 February 2019, 10:36 AM
P721 Early vedolizumab trough levels are associated with induction therapy outcome
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. O’Connell1, R. Corcoran1, R. Argue1, P. McDonagh1, M.S. Ismail2, G. Cullen3, G. Doherty3, K. Hartery1, M. Healy4, M. McCormack4, F. MacCarthy1, S. McKiernan1, A. O’Connor2, B. Ryan2, D. McNamara2, D. Kevans1

Created: Thursday, 30 January 2020, 10:12 AM
P721: A switch in the prevalence ratio of Crohn's disease vs. ulcerative colitis in Israel between 2003 and 2015 – a report from the epi-IIRN group
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Friedman M.*1, Odes S.2, Balicer R.3, Hoshen M.3, Cohen D.3, Rosenblum J.4, Zigman N.4, Goren I.4, Lederman N.5, Matz E.6, Dushnitzky D.6, Borovsky N.6, Gavish M.7, Focht G.1, Avitzour M.1, Axelrod R.1,7, Chowers Y.8, Eliakim R.9, Ben-Horin S.9, Dotan I.10, Israeli E.11, Levy Z.12, Benchimol E.13, Turner D.1

Created: Wednesday, 20 February 2019, 10:36 AM
P721: Effect of thalidomide on clinical remission in adult with refractory crohn disease, a multicentre, randomised, double-blind clinical trial
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

X. Peng*1, M. Zhi1, Q. Cao2, P. Hu1, X. Gao1

Created: Friday, 22 February 2019, 9:41 AM
P721: Faecal microbiota analysis with body composition and nutritional habits simultaneously amongst Crohn’s disease patients
Year: 2022
Source: ECCO'22
Authors: Bálint, A.(1);Bacsur, P.(1);Resál, T.(1);Jójárt, B.(2);Gyuris, Z.(3);Jaksa, G.(3);Pintér, L.(3);Takács, B.(4);Pál, S.(5);Gácser, A.(5);Szántó, K.J.(1);Rutka, M.(1);Bor, R.(1);Fábián, A.(1);Farkas, K.(1);Maléth, J.(2);Szepes, Z.(1);Molnár, T.(1);
Created: Friday, 11 February 2022, 3:56 PM
P721: Psychological care is needed and welcomed by patients with inflammatory bowel disease under routine care
Year: 2018
Source: ECCO '18 Vienna
Authors:

T. Lores1*, C. Goess1, C. Hrycek2, R. Grafton1, J. Hughes1, L. Cronin1, A.L. Burke3, K.L. Collins3, A. Chur-Hansen4, A. Mikocka-Walus5, J.M. Andrews1

Created: Thursday, 21 February 2019, 9:14 AM
P721: Treatment of Ulcerative Colitis with OSE-127 (lusvertikimab), a Strict IL-7Rα Antagonist, Non-Cytotoxic Monoclonal Antibody
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Corallo, F.(1)*;
Created: Friday, 14 July 2023, 11:12 AM
P722 Upadacitinib was not associated with anaemia in patients with moderately to severely active ulcerative colitis: Results from the U-ACHIEVE study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. D’Haens1, X. Hebuterne2, P.D.R. Higgins3, E.V. Loftus- Jr.4, W. Zhou5, A.P. Lacerda5, W. Xie6, J. Liu6, S. Danese7

Created: Thursday, 30 January 2020, 10:12 AM
P722: Compositional differences of gut microbiome using taxonomic profiling in patients with ulcerative colitis after treatment with vedolizumab
Year: 2022
Source: ECCO'22
Authors: Yoon, A.(1,2,3);Kim, K.(1);Oh, K.(1);Kim, E.S.(4);Kim, E.H.(4);Kim, S.(5);Jeong, J.Y.(4);Kweon, M.N.(5);Hwang, S.W.(1,3);Park, S.H.(1,3);Myung, S.J.(1);Yang, S.K.(1,3);Ye, B.D.(1,3);
Created: Friday, 11 February 2022, 3:56 PM
P722: Prediagnostic serum vitamin D levels and risk of inflammatory bowel disease: a pan-European, nested case-control study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Opstelten J.*1, Chan S.2,3, Hart A.2,3, van Schaik F.1, Siersema P.4, Lentjes E.5, Khaw K.-T.6, Luben R.6, Key T.7, Boeing H.8, Bergmann M.8, Overvad K.9, Palli D.10, Masala G.10, Racine A.11,12, Carbonnel F.11,12, Boutron-Ruault M.-C.11, Tjønneland A.13, Olsen A.13, Andersen V.14, Kaaks R.15, Kühn T.15, Tumino R.16, Trichopoulou A.17, Verschuren M.18,19, Witteman B.20,21, Oldenburg B.1

Created: Wednesday, 20 February 2019, 10:36 AM
P722: Results of the STAR study: management of ulcerative colitis in private practice in france, in the first years following diagnosis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Bourreille*1, S. Nancey2, A. Attar3, H. Sokol4, L. Peyrin-Biroulet5, Y. Bouhnik6, X. Roblin7, G. Bonnaud8

Created: Friday, 22 February 2019, 9:41 AM
P722: Symptom-based disease trajectories Identify a population of early super-responders in ulcerative colitis achieving complete disease control under targeted therapy
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Tran, F.(1,2)*;Brard, R.(3);Flechsenhar, K.(4);Aden, K.(1,2);Rosenstiel, P.(2);Agueusop, I.(3);Schreiber, S.(1,2);
Created: Friday, 14 July 2023, 11:12 AM